Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,405 GBX | 0.00% | 0.00% | +106.62% |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Sales 2021 | 338K 431K | Sales 2022 | 268K 342K | Capitalization | 87.45M 112M |
---|---|---|---|---|---|
Net income 2021 | -3M -3.83M | Net income 2022 | -5M -6.38M | EV / Sales 2021 | 200 x |
Net cash position 2021 | 8.06M 10.27M | Net cash position 2022 | 1.24M 1.58M | EV / Sales 2022 | 322 x |
P/E ratio 2021 |
-23.4
x | P/E ratio 2022 |
-17
x | Employees | 78 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 30.4% |
Current month | +31.31% | ||
1 month | +31.31% | ||
3 months | +77.85% | ||
6 months | +157.80% | ||
Current year | +106.62% |
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 46 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1,405 | 0.00% | 2,808 |
24-05-24 | 1,405 | 0.00% | 294 |
24-05-23 | 1,405 | 0.00% | 12 |
24-05-22 | 1,405 | 0.00% | 599 |
24-05-21 | 1,405 | 0.00% | 912 |
Delayed Quote London S.E., May 28, 2024 at 11:35 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+106.62% | 230M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- 4BB Stock